{ "meta": { "data_length": 1, "message": "Statement id stmt:hc:revlimid:0:0 retrieved successfully", "request_url": "https://api.moalmanac.org/statements?statement_id=stmt%3Ahc%3Arevlimid%3A0%3A0", "status": "success", "status_code": 200, "timestamp_elapsed": 0.002259, "timestamp_received": "2026-10-17T00:04:46.450651+00:00Z", "timestamp_returned": "2026-10-17T00:04:46.452910+00:00Z", "trace_id": "95c8d9bd-f4c8-4651-9eba-f55eb4c5d5bb" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://moalmanac.org", "last_updated": "2026-08-02" }, "data": [ { "id": "stmt:hc:revlimid:0:0", "type": "Statement", "description": "Health Canada approved lenalidomide for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogentic abnormalities.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-30:0", "type": "Contribution", "description": "Initial access of FDA approvals", "date": "2024-10-30", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } } ], "reportedIn": [ { "id": "doc:hc:revlimid", "type": "Document", "documentType": "Regulatory approval", "name": "Revlimid (lenalidomide) [product monograph]. HC.", "title": null, "aliases": [], "description": "Bristol-Myers Squibb Canada. Revlimid (lenalidomide) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074535.PDF. Published February 2024. Accessed June 2025.", "urls": [ "https://pdf.hres.ca/dpd_pm/00074535.PDF", "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79016" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:hc", "type": "Agent", "agentType": "organization", "name": "Health Canada", "description": "Regulatory agency that approves drugs for sale and use in Canada." }, "description": "The organization that published this document." }, { "name": "company", "value": "Bristol-Myers Squibb Canada", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Revlimid", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "lenalidomide", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2024-02-09", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2024-02-09", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:202", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:ncit:C3247", "conceptType": "Disease", "name": "Myelodysplastic Syndromes", "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:oncotree:MDS", "code": "MDS", "name": "Myelodysplastic Syndromes", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2025_10_03", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2025_10_03&field=NAME&search=Myelodysplastic+Syndromes+%28MDS%29" ] } } ], "extensions": [ { "name": "solid_tumor", "value": false, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:ncit:C3247", "code": "C3247", "name": "Myelodysplastic Syndrome", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C3247" ] } }, "objectTherapeutic": { "id": "tx:ncit:C2668", "conceptType": "Therapy", "name": "Lenalidomide", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:342369", "code": "342369", "name": "lenalidomide", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=342369" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:19026972", "code": "19026972", "name": "lenalidomide", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/19026972" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "Angiogenesis inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C2668", "code": "C2668", "name": "Lenalidomide", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2668" ] } }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:61", "present": true, "subject": { "id": "bmkr:61", "type": "CategoricalVariant", "name": "5q deletion", "constraints": [ { "type": "DefiningLocationConstraint", "location": { "id": "ga4gh:SL.KteBPIw-ySQLUSuG8gVPuVJnZW7kF7Js", "type": "SequenceLocation", "name": null, "aliases": [], "description": "The q arm of GRCh38 chromosome 5 (NC_000005.10), from the end of the centromere to the end of the chromosome.", "digest": "KteBPIw-ySQLUSuG8gVPuVJnZW7kF7Js", "sequenceReference": { "id": "ga4gh:SQ.aUiQCzCPZ2d0csHbMSbh2NzInhonSXwI", "type": "SequenceReference", "name": "NC_000005.10", "aliases": [ "ga4gh:SQ.aUiQCzCPZ2d0csHbMSbh2NzInhonSXwI", "refseq:NC_000005.10" ], "description": "GRCh38 chromosome 5 (RefSeq NC_000005.10).", "moleculeType": "genomic", "refgetAccession": "SQ.aUiQCzCPZ2d0csHbMSbh2NzInhonSXwI", "residueAlphabet": "na" }, "start": 50059807, "end": 181538259, "sequence": null }, "relations": [], "matchCharacteristic": { "primaryCoding": { "code": "is_within", "system": "ga4gh-gks-term:location-match" } } }, { "type": "CopyChangeConstraint", "copyChange": "loss" } ], "extensions": [ { "name": "biomarker_type", "value": "Copy number (arm level)" }, { "name": "chromosome", "value": "5" }, { "name": "arm", "value": "q" } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:hc:revlimid:0", "type": "Indication", "description": "REVLIMID (lenalidomide) is indicated for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Approval for this indication is based on red blood cell transfusion independence response rates. Overall survival benefit has not been demonstrated.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-30:0", "type": "Contribution", "description": "Initial access of FDA approvals", "date": "2024-10-30", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } } ], "reportedIn": [ { "id": "doc:hc:revlimid", "type": "Document", "documentType": "Regulatory approval", "name": "Revlimid (lenalidomide) [product monograph]. HC.", "title": null, "aliases": [], "description": "Bristol-Myers Squibb Canada. Revlimid (lenalidomide) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074535.PDF. Published February 2024. Accessed June 2025.", "urls": [ "https://pdf.hres.ca/dpd_pm/00074535.PDF", "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79016" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:hc", "type": "Agent", "agentType": "organization", "name": "Health Canada", "description": "Regulatory agency that approves drugs for sale and use in Canada." }, "description": "The organization that published this document." }, { "name": "company", "value": "Bristol-Myers Squibb Canada", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Revlimid", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "lenalidomide", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2024-02-09", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2024-02-09", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Approved", "description": "Current approval status." } ] }, "description": "The underlying Indication supporting this Statement." } ] } ] }